Nebenwirkungen · Remicade
Remicade 100 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 21
HOS-089922 · Präparat HOS-083941
Infections In the REACH study, infections were reported in 56.3% of randomised subjects treated with infliximab. Infections were reported more frequently for subjects who received q8 week as opposed to q12 week infusions (73.6% and 38.0%, respectively), while serious infections were reported for 3 subjects in the q8 week and 4 subjects in the q12 week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Three cases of pneumonia (1 serious) and 2 cases of herpes zoster (both non-serious) were reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-15T13:59:00Z · SHA-256 3fe5ec643ebd8b47f3d2adf8a19ade1224c614e70c07c2d563b0cf68054693ab · Passage 43d840ee92fec9cc5a82e24ff9b3c7adbb9709080715a55db1f84841c9e4c994 · Zeichen 26707–27345 im Abschnitt